FHTX Logo

Foghorn Therapeutics Inc. (FHTX) 

NASDAQ
Market Cap
$305.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
581 of 809
Rank in Industry
318 of 445

Largest Insider Buys in Sector

FHTX Stock Price History Chart

FHTX Stock Performance

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Activity of Foghorn Therapeutics Inc.

Over the last 12 months, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $2.64M worth of Foghorn Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Foghorn Therapeutics Inc. have bought $4.89M and sold $2.64M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 150,000 shares for transaction amount of $2.4M was made by Flagship Ventures Fund V General Partner LLC (10 percent owner) on 2020‑10‑27.

List of Insider Buy and Sell Transactions, Foghorn Therapeutics Inc.

2024-03-11SaleCavalie FannyChief Strategy/Bus Ops Officer
11,000
0.0249%
$6.56$72,134-13.54%
2023-08-16SaleAgresta SamuelChief Medical Officer
311,297
0.6823%
$8.25$2.57M-35.78%
2020-10-27PurchaseFlagship Ventures Fund V General Partner LLC10 percent owner
150,000
1.3579%
$16.00$2.4M-20.50%
2020-10-27PurchaseAbu Dhabi Investment Authority
150,000
1.3579%
$16.00$2.4M-20.50%
2020-10-27PurchaseDECICCO CARLChief Scientific Officer
5,500
0.0498%
$16.00$88,000-20.50%

Insider Historical Profitability

<0.0001%
Cavalie FannyChief Strategy/Bus Ops Officer
75992
0.1785%
$5.5201
Agresta SamuelChief Medical Officer
0
0%
$5.5201
Flagship Ventures Fund V General Partner LLC10 percent owner
9330878
22.1021%
$5.5210<0.0001%
Abu Dhabi Investment Authority
1231081
2.9161%
$5.5210<0.0001%
DECICCO CARLChief Scientific Officer
258397
0.6121%
$5.5210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Flagship Pioneering$85.04M22.9112.67M0%+$05.58
Fidelity Investments$18.06M4.862.69M-4.23%-$797,637.81<0.01
Raymond James Associates$14.97M4.032.23M+7.84%+$1.09M0.01
Euclidean Capital Llc$10.56M2.841.57M0%+$01.36
BlackRock$8.83M2.381.32M+0.73%+$63,765.13<0.0001
The Vanguard Group$7.4M1.991.1M+7.55%+$519,219.73<0.0001
Artal Group S A$4.84M1.3720,7200%+$00.03
Alphabet$3.36M0.91500,9010%+$00.13
Geode Capital Management$3.01M0.81448,411+0.01%+$409.36<0.0001
State Street$2.94M0.79437,664+3.56%+$100,878.13<0.0001
Point72 Asset Management$2.93M0.79437,369-19.01%-$688,654.010.01
Birchview Capital Lp$2.15M0.58320,9300%+$00.12
Driehaus Capital Management LLC$1.88M0.51280,382-18.43%-$424,997.930.02
Jacobs Levy Equity Management$1.45M0.39216,270+101.05%+$729,377.150.01
Northern Trust$1.31M0.35195,242-2.02%-$27,054.72<0.0001
Sio Capital Management LLC$816,419.000.22121,6720%+$00.29
Panagora$673,047.000.18100,305+3.39%+$22,062.49<0.01
Morgan Stanley$503,049.000.1474,970-28.68%-$202,259.65<0.0001
Millennium Management LLC$416,335.000.1162,047New+$416,335.00<0.0001
BNY Mellon$407,761.000.1160,769+6.24%+$23,961.47<0.0001
Invesco$376,042.000.156,042New+$376,042.00<0.0001
Charles Schwab$372,016.000.155,4420%+$0<0.0001
Nuveen$362,092.000.153,9630%+$0<0.0001
Exchange Traded Concepts, LLC$316,021.000.0947,097+118.7%+$171,521.090.01
Baker Bros Advisors LP$302,131.000.0845,0270%+$0<0.01
Acadian Asset Management$283,000.000.0842,367New+$283,000.00<0.01
Marshall Wace$245,089.000.0736,526New+$245,089.00<0.0001
ALTA WEALTH ADVISORS$201,515.000.0530,0320%+$00.1
RhumbLine Advisers$179,411.000.0526,739+3%+$5,220.16<0.0001
Cornercap Investment Counsel Inc$173,245.000.0525,8190%+$00.03
Citadel Advisors LLC$160,859.000.0423,973New+$160,859.00<0.0001
Gsa Capital Partners Llp$147,000.000.0421,855-47.08%-$130,756.350.01
UBS$136,709.000.0420,374-12.86%-$20,176.89<0.0001
Barclays$129,000.000.0419,242-41.52%-$91,591.21<0.0001
Susquehanna International Group$107,897.000.0316,080+41.91%+$31,865.85<0.0001
HSBC$105,958.000.0315,791+16.21%+$14,782.18<0.0001
JPMorgan Chase$94,196.000.0314,038+6.54%+$5,784.08<0.0001
Xtx Topco Ltd$90,236.000.0213,448New+$90,236.000.01
State Board of Administration of Florida$77,339.000.0212,474New+$77,339.00<0.0001
Bank of America$85,406.000.0212,728-56.22%-$109,676.39<0.0001
Goldman Sachs$76,635.000.0211,421-19.8%-$18,922.22<0.0001
Fiduciary Trust Co$72,998.000.0210,8790%+$0<0.01
AllianceBernstein$67,436.000.0210,0500%+$0<0.0001
American International Group$67,221.000.0210,018-0.85%-$577.06<0.0001
Deutsche Bank$64,376.000.029,594-3.99%-$2,677.30<0.0001
Royal Bank of Canada$57,000.000.028,448+29.95%+$13,136.72<0.0001
Wells Fargo$40,790.000.016,079+15.44%+$5,455.22<0.0001
NISA Investment Advisors, LLC$33,577.000.015,004+0.08%+$26.84<0.0001
Citigroup$22,714.000.013,385+15.41%+$3,033.01<0.0001
New York State Common Retirement Fund$16,000.00<0.012,422+28.69%+$3,567.30<0.0001